Literature DB >> 33809513

Survival Analysis in Single N2 Station Lung Adenocarcinoma: The Prognostic Role of Involved Lymph Nodes and Adjuvant Therapy.

Marco Chiappetta1,2, Filippo Lococo1,2, Giovanni Leuzzi3, Isabella Sperduti4, Emilio Bria1,5, Leonardo Petracca Ciavarella1,2, Felice Mucilli6, Pier Luigi Filosso7, Giovannibattista Ratto8, Lorenzo Spaggiari9, Francesco Facciolo10, Stefano Margaritora1,2.   

Abstract

BACKGROUND: Prognostic factors in patients with single mediastinal station (sN2) involvement continues to be a debated issue.
METHODS: Data on 213 adenocarcinoma patients with sN2 involvement and who had undergone complete anatomical lung resection and lymphadenectomy, were retrospectively reviewed. Clinical and pathological characteristics together with adjuvant therapy (AD) and node (N) status classifications (number of resected nodes (#RN), number of metastatic nodes (#MN), and node ratio (#MN/#RN = NR) were analyzed.
RESULTS: Univariable analysis confirmed that age (0.009), #MN (0.009), NR (0.003), #N1 involved stations (p = 0.003), and skip metastases (p = 0.005) were related to overall survival (OS). Multivariable analysis confirmed, as independent prognostic factors, age <66 years and NR with a three-year OS (3YOS) of 78.7% in NR < 10% vs. 46.6% in NR > 10%. In skip metastases, NR (HR 2.734, 95% CI 1.417-5.277, p = 0.003) and pT stage (HR2.136, 95% CI 1.001-4.557, p = 0.050) were confirmed as independent prognostic factors. AD did not influence the OS of patients with singular positive lymph nodes (p = 0.41), while in patients with multiple lymph nodes and AD, a significantly better 3YOS was demonstrated, i.e., 49.1% vs. 30% (p = 0.004). In patients with N2 + N1 involvement, age (p = 0.002) and AD (p = 0.022) were favorable prognostic factors.
CONCLUSIONS: Adenocarcinoma patients with single N2 station involvement had a favorable outcome in the case of skip metastases and low NR. Adjuvant therapy improves survival with multiple nodal involvement, while its role in single node involvement should be clarified.

Entities:  

Keywords:  NSCLC; adenocarcinoma; adjuvant therapy; lymph node; surgery

Year:  2021        PMID: 33809513      PMCID: PMC7998125          DOI: 10.3390/cancers13061326

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  23 in total

Review 1.  Bronchial arteries and lymphatics of the lung.

Authors:  Marc Riquet
Journal:  Thorac Surg Clin       Date:  2007-11       Impact factor: 1.750

2.  Prognostic Impact of the Number of Metastatic Lymph Nodes on the Eighth Edition of the TNM Classification of NSCLC.

Authors:  Shinya Katsumata; Keiju Aokage; Genichiro Ishii; Shoko Nakasone; Takashi Sakai; Satoshi Okada; Tomohiro Miyoshi; Kenta Tane; Masahiro Tsuboi
Journal:  J Thorac Oncol       Date:  2019-05-02       Impact factor: 15.609

3.  Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study.

Authors:  Byung Jo Park; Tae Ho Kim; Sumin Shin; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim; Jong Ho Cho
Journal:  J Thorac Oncol       Date:  2019-08-20       Impact factor: 15.609

4.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non-small-cell Lung Cancer.

Authors:  Kezhong Chen; Haiqing Chen; Fan Yang; Xizhao Sui; Xiao Li; Jun Wang
Journal:  Clin Lung Cancer       Date:  2017-04-12       Impact factor: 4.785

6.  Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.

Authors:  Hisashi Saji; Masahiro Tsuboi; Koichi Yoshida; Yasufumi Kato; Masaharu Nomura; Jun Matsubayashi; Toshitaka Nagao; Masatoshi Kakihana; Jitsuo Usuda; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

7.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

8.  External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy.

Authors:  Marco Chiappetta; Filippo Lococo; Giovanni Leuzzi; Isabella Sperduti; Leonardo Petracca-Ciavarella; Emilio Bria; Felice Mucilli; Pier Luigi Filosso; Giovanni Battista Ratto; Lorenzo Spaggiari; Francesco Facciolo; Stefano Margaritora
Journal:  Eur J Cardiothorac Surg       Date:  2020-12-01       Impact factor: 4.191

9.  Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non-small-cell Lung Cancer: A Propensity Score Matching Analysis.

Authors:  Lin Wang; Cheng Zhan; Jie Gu; Junjie Xi; Zongwu Lin; Liang Xue; Di Ge; Qun Wang
Journal:  Clin Lung Cancer       Date:  2018-12-19       Impact factor: 4.785

Review 10.  Role of radiation oncology in modern multidisciplinary cancer treatment.

Authors:  Vincenzo Valentini; Luca Boldrini; Silvia Mariani; Mariangela Massaccesi
Journal:  Mol Oncol       Date:  2020-06-22       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.